世界の弱毒化ワクチン市場

【英語タイトル】Global Attenuated Vaccines Market

Future Market Insightsが出版した調査資料(FMI22NV0039)・商品コード:FMI22NV0039
・発行会社(調査会社):Future Market Insights
・発行日:2022年5月
・ページ数:307
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single Price(1名様閲覧用)USD5,000 ⇒換算¥740,000見積依頼/購入/質問フォーム
Site Licence(同一拠点内共有可)USD7,500 ⇒換算¥1,110,000見積依頼/購入/質問フォーム
Enterprisewide(複数拠点内共有可)USD10,000 ⇒換算¥1,480,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Future Market Insights社の当調査レポートでは、世界の弱毒化ワクチン市場を対象に総合的に調査・分析を行い、エグゼクティブサマリー、市場概要、市場背景、市場分析&予測、ワクチンタイプ別(一価ワクチン、多価ワクチン)分析、疾患別(インフルエンザ、MMR、ポリオ、水疱瘡、その他)分析、投与経路別(筋肉内、皮下、経口、鼻腔内、静脈内)分析、エンドユーザー別(病院、クリニック、その他)分析、地域別(北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ)分析、市場構造分析、競争分析、仮定、調査手法などの内容をまとめております。なお、当書に掲載されている企業情報には、Merck & Co., Inc.、GlaxoSmithKline plc、Pfizer Inc.、Sanofi、Astellas Pharma、Johnson & Johnson、CSL Limited、Serum Institute of India Pvt. Ltd.などが含まれています。
・エグゼクティブサマリー
・市場概要
・市場背景
・市場分析&予測
・世界の弱毒化ワクチン市場規模:ワクチンタイプ別
- 一価ワクチンの市場規模
- 多価ワクチンの市場規模
・世界の弱毒化ワクチン市場規模:疾患別
- インフルエンザワクチンの市場規模
- MMRワクチンの市場規模
- ポリオワクチンの市場規模
- 水疱瘡ワクチンの市場規模
- その他疾患ワクチンの市場規模
・世界の弱毒化ワクチン市場規模:投与経路別
- 筋肉内ワクチンの市場規模
- 皮下ワクチンの市場規模
- 経口ワクチンの市場規模
- 鼻腔内ワクチンの市場規模
- 静脈内ワクチンの市場規模
・世界の弱毒化ワクチン市場規模:エンドユーザー別
- 病院における市場規模
- クリニックにおける市場規模
- その他エンドユーザーにおける市場規模
・世界の弱毒化ワクチン市場規模:地域別
- 北米の弱毒化ワクチン市場規模
- 中南米の弱毒化ワクチン市場規模
- ヨーロッパの弱毒化ワクチン市場規模
- 東アジアの弱毒化ワクチン市場規模
- 南アジアの弱毒化ワクチン市場規模
- オセアニアの弱毒化ワクチン市場規模
- 中東・アフリカの弱毒化ワクチン市場規模
・市場構造分析
・競争分析
・仮定
・調査手法

Attenuated Vaccines Market: Global Industry Analysis 2017-2021 and Opportunity Assessment 2022-2032

A recent market study published by FMI on Attenuated Vaccines offers a global industry analysis for 2017-2021 and opportunity assessment for 2022-2032. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

Market Segmentation
The global Attenuated Vaccines Market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.

By Vaccines Type • Monovalent Attenuated Vaccines
• Multivalent Attenuated Vaccines

By Indication • Influenza
• Measles, Mumps & Rubella (MMR)
• Polio
• Chickenpox
• Shingles
• Rotavirus
• Other Indications

By Route of Administration • Intramuscular
• Subcutaneous
• Oral
• Intranasal
• Intravenous

By Age Group • Pediatrics
• Adolescents
• Adults
• Geriatric Patients

By End User • Hospitals
• Clinics
• Other End Users

By Region • North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Report Chapters
Executive Summary
The executive summary of the Attenuated Vaccines Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Attenuated Vaccines.
Chapter 01 – Market Overview
Readers can find the detailed segmentation and definition of the Attenuated Vaccines Market in this chapter, which will help to understand basic information about Attenuated Vaccines. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Attenuated Vaccines Market report.
Chapter 02 – Market Background
This chapter includes detailed analysis of the product processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors – relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.
Chapter 03 – Global Attenuated Vaccines Market Demand Analysis 2017-2021 and Forecast, 2022-2032
The chapter include historical market value (US$ 4,170.2 Million) analysis (2017-2021) and current and future market value (US$ 4,451.7 Million) and volume (6.8%) projections (2022-2032). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.
Chapter 04 – Global Attenuated Vaccines Market – Pricing Analysis
Based on By Vaccines Type, the pricing analysis chapter include regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.
Chapter 05 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Vaccines Type
Based on By Vaccines Type, Attenuated Vaccines Market is segmented into Monovalent Attenuated Vaccines and Multivalent Attenuated Vaccines. This section also offers market attractiveness analysis based on By Vaccines Type. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Vaccines Type.
Chapter 06 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
Based on By Indication, Attenuated Vaccines Market is segmented into Influenza, Measles, Mumps & Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications. This section also offers market attractiveness analysis based on By Indication. Readers can also find value forecast and y-o-y growth comparison for all above mentioned By Indication.
Chapter 07 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Based on By Route of Administration, Attenuated Vaccines Market is segmented into Intramuscular, Subcutaneous, Oral, Intranasal, Intravenous. This section also offers market attractiveness analysis based on By Route of Administration. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Route of Administration.
Chapter 08 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Age Group
Based on By Age Group, Attenuated Vaccines Market is segmented into Pediatrics, Adolescents, Adults, Geriatric Patients. This section a By Age Group zlso offers market attractiveness analysis based on By Age Group. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned Age Group.
Chapter 09 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By End User
Based on By End User, Attenuated Vaccines Market is segmented into Hospitals, Clinics, Other End Users. This section a By End User zlso offers market attractiveness analysis based on By End User. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned End User.
Chapter 10 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Region
Based on By Region, Attenuated Vaccines Market is segmented North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.
Chapter 11 – North America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of the Attenuated Vaccines in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.
Chapter 12 – Latin America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the Latin America region.
Chapter 13 – Europe Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 14 – East Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 15 – South Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 16 – Oceania Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the Oceania region, along with a country-wise assessment that includes the Australia and New Zealand. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 17 – Middle East and Africa Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 18 – Key Countries Attenuated Vaccines Market Analysis 2017–2021 and Forecast 2022–2032
This chapter offers insights into how the Attenuated Vaccines Market is expected to grow in major countries globally.
Chapter 19 – Market Structure Analysis- Global Assessment
This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.
Chapter 20 – Competition Deep Dive (Tentative List)
This chapter includes company overview, product portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd.
Chapter 21 – Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Attenuated Vaccines Market report.
Chapter 22 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Attenuated Vaccines Market.

❖ レポートの目次 ❖

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Vaccine Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Bn) Analysis By Vaccine Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Vaccine Type, 2022-2032

        5.3.1. Monovalent Vaccines

        5.3.2. Multivalent Vaccines

    5.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Vaccine Type, 2022-2032

6. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Bn) Analysis By Indication, 2017-2021

    6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication, 2022-2032

        6.3.1. Influenza 

        6.3.2. Measles, Mumps & Rubella (MMR)

        6.3.3. Polio

        6.3.4. Chickenpox

        6.3.5. Shingles

        6.3.6. Rotavirus

        6.3.7. Other Indications

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032

7. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Bn) Analysis By Route of Administration, 2017-2021

    7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Route of Administration, 2022-2032

        7.3.1. Intramuscular

        7.3.2. Subcutaneous

        7.3.3. Oral

        7.3.4. Intranasal

        7.3.5. Intravenous

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032

8. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Age Group

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Bn) Analysis By Age Group, 2017-2021

    8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Age Group, 2022-2032

        8.3.1. Pediatric

        8.3.2. Adolcents

        8.3.3. Adults

        8.3.4. Geriatric

    8.4. Y-o-Y Growth Trend Analysis By Age Group, 2017-2021

    8.5. Absolute $ Opportunity Analysis By Age Group, 2022-2032

9. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Bn) Analysis By End User, 2017-2021

    9.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End User, 2022-2032

        9.3.1. Hospitals

        9.3.2. Clinics

        9.3.3. Others

    9.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021

    9.5. Absolute $ Opportunity Analysis By End User, 2022-2032

10. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    10.1. Introduction

    10.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021

    10.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. MEA

    10.4. Market Attractiveness Analysis By Region

11. North America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Value (US$ Bn)ed States

            11.2.1.2. Canada

        11.2.2. By Vaccine Type

        11.2.3. By Indication

        11.2.4. By Route of Administration

        11.2.5. By Age Group

        11.2.6. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Vaccine Type

        11.3.3. By Indication

        11.3.4. By Route of Administration

        11.3.5. By Age Group

        11.3.6. By End User

    11.4. Key Takeaways

12. Latin America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Brazil

            12.2.1.2. Mexico

            12.2.1.3. Rest of Latin America

        12.2.2. By Vaccine Type

        12.2.3. By Indication

        12.2.4. By Route of Administration

        12.2.5. By Age Group

        12.2.6. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Vaccine Type

        12.3.3. By Indication

        12.3.4. By Route of Administration

        12.3.5. By Age Group

        12.3.6. By End User

    12.4. Key Takeaways

13. Europe Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. Germany

            13.2.1.2. U.K.

            13.2.1.3. France

            13.2.1.4. Spain

            13.2.1.5. Italy

            13.2.1.6. Rest of Europe

        13.2.2. By Vaccine Type

        13.2.3. By Indication

        13.2.4. By Route of Administration

        13.2.5. By Age Group

        13.2.6. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Vaccine Type

        13.3.3. By Indication

        13.3.4. By Route of Administration

        13.3.5. By Age Group

        13.3.6. By End User

    13.4. Key Takeaways

14. East Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Vaccine Type

        14.2.3. By Indication

        14.2.4. By Route of Administration

        14.2.5. By Age Group

        14.2.6. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Vaccine Type

        14.3.3. By Indication

        14.3.4. By Route of Administration

        14.3.5. By Age Group

        14.3.6. By End User

    14.4. Key Takeaways

15. South Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    15.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    15.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        15.2.1. By Country

            15.2.1.1. India

            15.2.1.2. ASEAN

            15.2.1.3. Rest of South Asia

        15.2.2. By Vaccine Type

        15.2.3. By Indication

        15.2.4. By Route of Administration

        15.2.5. By Age Group

        15.2.6. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Vaccine Type

        15.3.3. By Indication

        15.3.4. By Route of Administration

        15.3.5. By Age Group

        15.3.6. By End User

    15.4. Key Takeaways

16. Oceania Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    16.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    16.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        16.2.1. By Country

            16.2.1.1. Australia

            16.2.1.2. New Zealand

        16.2.2. By Vaccine Type

        16.2.3. By Indication

        16.2.4. By Route of Administration

        16.2.5. By Age Group

        16.2.6. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Vaccine Type

        16.3.3. By Indication

        16.3.4. By Route of Administration

        16.3.5. By Age Group

        16.3.6. By End User

    16.4. Key Takeaways

17. MEA Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    17.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021

    17.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032

        17.2.1. By Country

            17.2.1.1. GCC Countries

            17.2.1.2. South Africa

            17.2.1.3. Israel

            17.2.1.4. Rest of MEA

        17.2.2. By Vaccine Type

        17.2.3. By Indication

        17.2.4. By Route of Administration

        17.2.5. By Age Group

        17.2.6. By End User

    17.3. Market Attractiveness Analysis

        17.3.1. By Country

        17.3.2. By Vaccine Type

        17.3.3. By Indication

        17.3.4. By Route of Administration

        17.3.5. By Age Group

        17.3.6. By End User

    17.4. Key Takeaways

18. Key Countries Attenuated Vaccines Market Analysis

    18.1. Value (US$ Bn)ed States

        18.1.1. Pricing Analysis

        18.1.2. Market Share Analysis, 2021

            18.1.2.1. By Vaccine Type

            18.1.2.2. By Indication

            18.1.2.3. By Route of Administration

            18.1.2.4. By Age Group

            18.1.2.5. By End User

    18.2. Canada

        18.2.1. Pricing Analysis

        18.2.2. Market Share Analysis, 2021

            18.2.2.1. By Vaccine Type

            18.2.2.2. By Indication

            18.2.2.3. By Route of Administration

            18.2.2.4. By Age Group

            18.2.2.5. By End User

    18.3. Brazil

        18.3.1. Pricing Analysis

        18.3.2. Market Share Analysis, 2021

            18.3.2.1. By Vaccine Type

            18.3.2.2. By Indication

            18.3.2.3. By Route of Administration

            18.3.2.4. By Age Group

            18.3.2.5. By End User

    18.4. Mexico

        18.4.1. Pricing Analysis

        18.4.2. Market Share Analysis, 2021

            18.4.2.1. By Vaccine Type

            18.4.2.2. By Indication

            18.4.2.3. By Route of Administration

            18.4.2.4. By Age Group

            18.4.2.5. By End User

    18.5. Rest of Latin America

        18.5.1. Pricing Analysis

        18.5.2. Market Share Analysis, 2021

            18.5.2.1. By Vaccine Type

            18.5.2.2. By Indication

            18.5.2.3. By Route of Administration

            18.5.2.4. By Age Group

            18.5.2.5. By End User

    18.6. Germany

        18.6.1. Pricing Analysis

        18.6.2. Market Share Analysis, 2021

            18.6.2.1. By Vaccine Type

            18.6.2.2. By Indication

            18.6.2.3. By Route of Administration

            18.6.2.4. By Age Group

            18.6.2.5. By End User

    18.7. U.K.

        18.7.1. Pricing Analysis

        18.7.2. Market Share Analysis, 2021

            18.7.2.1. By Vaccine Type

            18.7.2.2. By Indication

            18.7.2.3. By Route of Administration

            18.7.2.4. By Age Group

            18.7.2.5. By End User

    18.8. France

        18.8.1. Pricing Analysis

        18.8.2. Market Share Analysis, 2021

            18.8.2.1. By Vaccine Type

            18.8.2.2. By Indication

            18.8.2.3. By Route of Administration

            18.8.2.4. By Age Group

            18.8.2.5. By End User

    18.9. Spain

        18.9.1. Pricing Analysis

        18.9.2. Market Share Analysis, 2021

            18.9.2.1. By Vaccine Type

            18.9.2.2. By Indication

            18.9.2.3. By Route of Administration

            18.9.2.4. By Age Group

            18.9.2.5. By End User

    18.10. Italy

        18.10.1. Pricing Analysis

        18.10.2. Market Share Analysis, 2021

            18.10.2.1. By Vaccine Type

            18.10.2.2. By Indication

            18.10.2.3. By Route of Administration

            18.10.2.4. By Age Group

            18.10.2.5. By End User

    18.11. Rest of Europe

        18.11.1. Pricing Analysis

        18.11.2. Market Share Analysis, 2021

            18.11.2.1. By Vaccine Type

            18.11.2.2. By Indication

            18.11.2.3. By Route of Administration

            18.11.2.4. By Age Group

            18.11.2.5. By End User

    18.12. China

        18.12.1. Pricing Analysis

        18.12.2. Market Share Analysis, 2021

            18.12.2.1. By Vaccine Type

            18.12.2.2. By Indication

            18.12.2.3. By Route of Administration

            18.12.2.4. By Age Group

            18.12.2.5. By End User

    18.13. Japan

        18.13.1. Pricing Analysis

        18.13.2. Market Share Analysis, 2021

            18.13.2.1. By Vaccine Type

            18.13.2.2. By Indication

            18.13.2.3. By Route of Administration

            18.13.2.4. By Age Group

            18.13.2.5. By End User

    18.14. South Korea

        18.14.1. Pricing Analysis

        18.14.2. Market Share Analysis, 2021

            18.14.2.1. By Vaccine Type

            18.14.2.2. By Indication

            18.14.2.3. By Route of Administration

            18.14.2.4. By Age Group

            18.14.2.5. By End User

    18.15. India

        18.15.1. Pricing Analysis

        18.15.2. Market Share Analysis, 2021

            18.15.2.1. By Vaccine Type

            18.15.2.2. By Indication

            18.15.2.3. By Route of Administration

            18.15.2.4. By Age Group

            18.15.2.5. By End User

    18.16. ASEAN

        18.16.1. Pricing Analysis

        18.16.2. Market Share Analysis, 2021

            18.16.2.1. By Vaccine Type

            18.16.2.2. By Indication

            18.16.2.3. By Route of Administration

            18.16.2.4. By Age Group

            18.16.2.5. By End User

    18.17. Rest of South Asia

        18.17.1. Pricing Analysis

        18.17.2. Market Share Analysis, 2021

            18.17.2.1. By Vaccine Type

            18.17.2.2. By Indication

            18.17.2.3. By Route of Administration

            18.17.2.4. By Age Group

            18.17.2.5. By End User

    18.18. Australia

        18.18.1. Pricing Analysis

        18.18.2. Market Share Analysis, 2021

            18.18.2.1. By Vaccine Type

            18.18.2.2. By Indication

            18.18.2.3. By Route of Administration

            18.18.2.4. By Age Group

            18.18.2.5. By End User

    18.19. New Zealand

        18.19.1. Pricing Analysis

        18.19.2. Market Share Analysis, 2021

            18.19.2.1. By Vaccine Type

            18.19.2.2. By Indication

            18.19.2.3. By Route of Administration

            18.19.2.4. By Age Group

            18.19.2.5. By End User

    18.20. GCC Countries

        18.20.1. Pricing Analysis

        18.20.2. Market Share Analysis, 2021

            18.20.2.1. By Vaccine Type

            18.20.2.2. By Indication

            18.20.2.3. By Route of Administration

            18.20.2.4. By Age Group

            18.20.2.5. By End User

    18.21. South Africa

        18.21.1. Pricing Analysis

        18.21.2. Market Share Analysis, 2021

            18.21.2.1. By Vaccine Type

            18.21.2.2. By Indication

            18.21.2.3. By Route of Administration

            18.21.2.4. By Age Group

            18.21.2.5. By End User

    18.22. Israel

        18.22.1. Pricing Analysis

        18.22.2. Market Share Analysis, 2021

            18.22.2.1. By Vaccine Type

            18.22.2.2. By Indication

            18.22.2.3. By Route of Administration

            18.22.2.4. By Age Group

            18.22.2.5. By End User

    18.23. Rest of MEA

        18.23.1. Pricing Analysis

        18.23.2. Market Share Analysis, 2021

            18.23.2.1. By Vaccine Type

            18.23.2.2. By Indication

            18.23.2.3. By Route of Administration

            18.23.2.4. By Age Group

            18.23.2.5. By End User

19. Market Structure Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Market Share Analysis of Top Players

        19.3.1. By Regional

        19.3.2. By Vaccine Type

        19.3.3. By Indication

        19.3.4. By Route of Administration

        19.3.5. By Age Group

        19.3.6. By End User

20. Competition Analysis

    20.1. Competition Deep Dive

        20.1.1. GlaxoSmithKline

            20.1.1.1. Overview

            20.1.1.2. Product Portfolio

            20.1.1.3. Profitability by Market Segments

            20.1.1.4. Sales Footprint

            20.1.1.5. Strategy Overview

                20.1.1.5.1. Marketing Strategy

        20.1.2. Merck

            20.1.2.1. Overview

            20.1.2.2. Product Portfolio

            20.1.2.3. Profitability by Market Segments

            20.1.2.4. Sales Footprint

            20.1.2.5. Strategy Overview

                20.1.2.5.1. Marketing Strategy

        20.1.3. Pfizer

            20.1.3.1. Overview

            20.1.3.2. Product Portfolio

            20.1.3.3. Profitability by Market Segments

            20.1.3.4. Sales Footprint

            20.1.3.5. Strategy Overview

                20.1.3.5.1. Marketing Strategy

        20.1.4. Sanofi

            20.1.4.1. Overview

            20.1.4.2. Product Portfolio

            20.1.4.3. Profitability by Market Segments

            20.1.4.4. Sales Footprint

            20.1.4.5. Strategy Overview

                20.1.4.5.1. Marketing Strategy

        20.1.5. Astellas Pharma

            20.1.5.1. Overview

            20.1.5.2. Product Portfolio

            20.1.5.3. Profitability by Market Segments

            20.1.5.4. Sales Footprint

            20.1.5.5. Strategy Overview

                20.1.5.5.1. Marketing Strategy

        20.1.6. Johnson and Johnson

            20.1.6.1. Overview

            20.1.6.2. Product Portfolio

            20.1.6.3. Profitability by Market Segments

            20.1.6.4. Sales Footprint

            20.1.6.5. Strategy Overview

                20.1.6.5.1. Marketing Strategy

        20.1.7. CSL

            20.1.7.1. Overview

            20.1.7.2. Product Portfolio

            20.1.7.3. Profitability by Market Segments

            20.1.7.4. Sales Footprint

            20.1.7.5. Strategy Overview

                20.1.7.5.1. Marketing Strategy

        20.1.8. Serum Institute Of India

            20.1.8.1. Overview

            20.1.8.2. Product Portfolio

            20.1.8.3. Profitability by Market Segments

            20.1.8.4. Sales Footprint

            20.1.8.5. Strategy Overview

                20.1.8.5.1. Marketing Strategy

21. Assumptions & Acronyms Used

22. Research Methodology



★調査レポート[世界の弱毒化ワクチン市場] (コード:FMI22NV0039)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の弱毒化ワクチン市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆